Strategic imperatives for biotech firms in light of the latest market dynamics and investor behaviors.
Divya Yerraguntla
Advertisement
Vice President, Asset Strategy, Syneos Health
Articles by Divya Yerraguntla
Choosing the right team and implementing structure headline necessities for launch.
Advertisement
Latest Updated Articles
How Should Biotechs Strategize for 2025Published: August 12th 2024 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
2
AI Built for Pharma—Out-of-the-Box Wins on Time, Risk, and ROI
3
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
4
FDA Announces New Biosimilar-Targeted Draft Guidance
5
